Logo

American Heart Association

  38
  0


Final ID:

ANGPTL3 inhibitors for reduction of cardiovascular disease risk

  • Rosenson, Robert  ( MT SINAI SCHOOL MEDICINE , New York , New York , United States )
  • Author Disclosures:
    Robert Rosenson: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Intercept Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Editas Medicine:Past (completed) ; Consultant:CRISPER Therapeutics:Past (completed) ; Consultant:Arrowhead:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now) ; Research Funding (PI or named investigator):89Bio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Triglyceride-Rich Lipoproteins in Cardiovascular and Metabolic Disease

Friday, 11/07/2025 , 12:30PM - 01:45PM

Cardiovascular Seminar

More abstracts from these authors:
Discussant

Lingvay Ildiko, Rosenson Robert

Associations of Predicted CVD risk by the PREVENT Equation with AI-analyzed Coronary Atherosclerotic Plaque Characteristics

Gurevitz Chen, Fisher Rebecca, Muntner Paul, Fisher Edward, Rosenson Robert

You have to be authorized to contact abstract author. Please, Login
Not Available